A Q&A with Jake Haling, Head of Oncology Drug Discovery in San Diego, on induced proximity and how it could open new paths to treat cancer.

What drives someone to dedicate their career to reimagining medicine? Three women at Novartis share their deeply personal and unique stories.

Max leads AI innovation in pharmaceutical development at Novartis. His story reflects how cutting-edge technology is combined with human expertise for meaningful impact.

Manju Ujjini, Head of Lead Discovery for our Global Health Biomedical Research group, discusses what’s next for his team in drug discovery

A Q&A with Bryan Laffitte, who leads a Novartis team that’s using the tools of genetic medicine to innovate new therapies for neuromuscular and neurodegenerative conditions.

Novartis is proud to share that TIME has recognized Victor Bultó and Thierry Diagana among the most influential people shaping the future of health. Learn more about what drives our honorees.

Leprosy is one of the world’s oldest infectious diseases – yet there are still around 200,000 cases every year¹. As the only supplier of multidrug therapy, in January 2026 Novartis renewed its partnership to provide the medicine via the WHO, protecting vital access to treatment.

Novartis-Harvard team identifies a new type of cell that is key to the disease.

In Wendi Yajnik’s quest to find new technologies that could transform medicine, relationships are priority No. 1.